The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene autotemcel, branded Casgevy, for severe sickle cell disease, and later the EMA approved it for use in the EU. NICE has since recommended Casgevy for NHS use through managed access. While these are haematology indications, they establish the feasibility of regulated gene editing products entering routine care and provide a template for evidence standards, pharmacovigilance and service configuration. Oncology is next in line.
Real fact: NICE published guidance in February 2025 recommending exagamglogene autotemcel for severe sickle cell disease in people aged 12 years and over with managed access arrangements in England.
This feature examines CRISPR therapies in oncology as of October 2025. It outlines the core editing systems, the emerging therapeutic strategies ex vivo and in vivo, and the clinical evidence in late-stage pipelines. It then assesses UK regulatory and commissioning pathways and sets out the pharmacy and operational implications for NHS providers.
CRISPR systems tailored for oncology
The foundational technology uses programmable nucleases to introduce precise changes in DNA. SpCas9 remains the workhorse, but clinical programmes now evaluate base editors and early prime editing tools to increase precision and reduce double-strand breaks. Base editors install targeted nucleotide conversions without cutting both DNA strands, which may lower the risk of translocations and improve product yields in engineered cells. Prime editors can make small insertions or corrections with fewer byproducts, although their oncology clinical experience is limited compared to Cas9 or base editing. Developers pair these editors with guide RNAs and delivery platforms suited to the target tissue and indication.
Safety engineering typically includes multiplex edits to remove endogenous receptors, reduce exhaustion pathways and add therapeutic transgenes. Assays for off-target activity, vector integration and genotoxicity are a central part of release and comparability packages presented to regulators. EMA and MHRA guidance for advanced therapies stresses comparability when products evolve during development, an issue that is acute for iterative cell products.
Therapeutic strategies for ex vivo enhancement of T cells
Most oncology programmes use ex vivo editing of patient or donor T cells. Two streams dominate.
Autologous CRISPR-edited T cells aim to improve persistence and potency. Programmes knock out genes that drive exhaustion or remove targets that cause self-fratricide in T cell malignancies. Allogeneic CRISPR CAR T seeks to deliver off-the-shelf therapy by editing healthy donor T cells to remove T cell receptor signalling and key HLA molecules, which can reduce graft versus host and host rejection. Sponsors often add edits to checkpoint genes to sustain activity in hostile tumour microenvironments.
A notable example is CRISPR Therapeutics’ CD19-directed allogeneic portfolio. Phase 1 and 2 studies with CTX110 and CTX112 have shown activity in relapsed B-cell malignancies with signals of complete response at higher doses and evolving safety management. Caribou Biosciences’ CB 010 uses a hybrid RNA-DNA CRISPR platform and incorporates PD-1 disruption to prolong activity. Clinical updates across 2024 and 2025 described continued development towards later-stage studies. Base edited approaches, such as BEAM 201, an allogeneic anti-CD7 CAR T for T cell malignancies, are designed to avoid self-targeting and improve manufacturing consistency.
Early solid tumour work focuses on edited TCR therapies that replace natural T cell receptors with patient-specific receptors against neoantigens, combined with additional edits for persistence. A first-in-human CRISPR-engineered TCR study reported feasibility and on-target editing across multiple solid cancers. Although responses were modest, the platform showed that multiplex editing and bespoke TCRs could be manufactured and safely infused.
Therapeutic strategies for in vivo editing at the tumour site
Direct in vivo editing in oncology is earlier in development than ex vivo approaches. Delivery is the major constraint. Viral vectors such as AAV offer efficient transduction but limit cargo and raise integration and immunity concerns. Non-viral platforms such as lipid nanoparticles can deliver Cas9 mRNA and guide RNA transiently and are suited to liver targeting. Companies have advanced LNP-based in vivo editing in non-oncology programmes, establishing a translational playbook that oncology developers seek to adapt for tumours and metastatic niches. Strategies under evaluation include tumour-targeted LNPs and locoregional administration to reach peritoneal or pleural disease while limiting systemic exposure.
Clinical landscape, the late 2025 snapshot
Haematological malignancies
B-cell malignancies remain the lead indications for CRISPR CAR T. CTX110 and CTX112 continue in multi-centre trials for relapsed or refractory B-cell non-Hodgkin lymphoma, with sponsors reporting durable responses in some patients and manageable safety. Caribou’s CB 010 ANTLER study has expanded to additional lines of therapy, with company communications signalling continued interaction with regulators on next steps. For T cell malignancies, BEAM 201 is in phase 1 and aims to overcome fratricide through multiplex base edits. Peer-reviewed outcomes are limited, but conference abstracts outline acceptable acute safety and early activity in small cohorts.
Solid tumours
Solid tumour signals are preliminary. The PACT Pharma academic collaboration demonstrated the feasibility of manufacturing bespoke CRISPR-edited TCR T cells for advanced solid cancers, showing evidence of tumour trafficking but limited objective responses. Current industry programmes are consolidating manufacturing, target selection and conditioning regimens to improve engraftment and function. Combination strategies with cytokines, checkpoint blockade or oncolytic platforms are under consideration to remodel the tumour microenvironment.
Approvals to date and oncology read across
Casgevy’s approvals do not answer cancer-specific questions. However, they demonstrate that regulated gene editing products can meet quality, safety and efficacy bars in major jurisdictions and be commissioned in the NHS with managed access. This precedent informs expectations for oncology. It shows how long-term follow-up, registries and manufacturing comparability are operationalised and how commissioning teams manage high upfront costs for small patient numbers. From bench to bedside: delivery challenges that determine success.
Vector and payload choices
Oncology applications must balance editing efficiency with safety. AAV-based systems can achieve high local transduction but face neutralising antibodies and potential integration risks. Non-viral LNPs are transient and scalable but require targeting ligands or locoregional delivery to concentrate the dose in tumours. Manufacturing controls must quantify residual impurities, replication-competent virus in lentiviral steps, and off-target edits by unbiased assays. EMA guidance and inspectorate consultations in 2025 emphasised updates to GMP specific to ATMPs, reinforcing expectations for in-process controls and comparability when sponsors modify product design during development.
Cell manufacturing logistics
Ex vivo oncology therapies require reliable apheresis, cryoshipment, editing, expansion and timely return to the clinic. Allogeneic models remove the apheresis step and can reduce vein-to-vein times. However, they introduce new release and inventory controls to manage multiple pre-made lots with patient matching and HLA considerations. The UK has moved to enable modular and point-of-care manufacture for ATMPs, allowing production closer to patients under MHRA oversight, which could reduce lead times and improve capacity utilisation for regional cancer centres.
Clinical infrastructure and multidisciplinary delivery
Trusts delivering gene-edited cell therapies need protected clean areas for receipt and thaw, a secure chain of custody, qualified staff for administration and 24-hour escalation pathways. Oncology services will adapt CAR T infrastructures established for autologous products, but gene editing cancer treatment adds release testing and long-term molecular follow-up requirements. NHS England’s ATMP Programme already commissions complex cell therapies in designated centres, providing a governance template for site selection, training and outcomes tracking.
The role of the specialist pharmacist
Specialist pharmacists sit at the operational core of CRISPR oncology. Responsibilities include verification of release documentation, reconciliation of the chain of identity and the chain of custody, environmental and temperature monitoring, and preparation or oversight of thaw and infusion steps. Pharmacists coordinate pre-medication plans, cytokine release syndrome readiness, and tocilizumab and steroid availability. They manage controlled documentation for deviations, adverse events and product complaints. The Specialist Pharmacy Service has issued institutional readiness guidance for gene therapy, highlighting governance, aseptic services, training, waste and biosafety considerations. These frameworks extend naturally to CRISPR-edited products.
Evidence standards, design questions, and safety monitoring
Late-stage oncology trials will need to resolve recurring design challenges. For allogeneic cell therapies, appropriate comparators may include standard of care or autologous CAR T, where available. Endpoints must capture depth and duration of response, event-free survival and health-related quality of life, with follow-up extending beyond 24 months to assess durability and delayed effects. For solid tumours, multi-arm designs that stratify by target and add modular edits over time will require strict comparability plans.
Safety must be addressed for target off-tumour risks for edited TCRs and CARs, insertional events, chromosomal rearrangements and replication-competent vectors where applicable. Off-target editing analysis should combine in silico predictions with unbiased assays in the final product and in patient samples where feasible. Long-term follow-up akin to gene therapy expectations will be standard, with registries capturing secondary malignancy signals and late toxicities. EMA guidance for investigational ATMPs entering into effect in 2025 underscores these requirements.
Reimbursement and NICE appraisal
NICE already appraises advanced therapies through technology appraisals that consider small cohorts, uncertain long-term outcomes and high upfront costs. For Casgevy, managed access allowed data collection while enabling patient treatment in England. Oncology applications will likely seek similar arrangements, especially for small B-cell indications or rare solid tumour targets. Payment models could include milestone-based or outcomes-linked contracts to balance uncertainty and affordability. Commissioners will require clear eligible population definitions, referral pathways and capacity plans to prevent regional inequity.
Ethics and public trust are separating somatic therapy from germline editing
Public discourse often conflates somatic gene editing in patients with germline editing in embryos. The UK ethical landscape draws a clear boundary. National bodies have called for continued development of somatic editing under robust oversight, while maintaining restrictions on heritable editing. Ethical reviews emphasise transparency on risks, equitable access and inclusive decision making as clinical use expands. For oncology, this means frank communication about uncertainties, long-term follow-up commitments and fair selection for limited slots at commissioned centres.
What success looks like for UK oncology services
A realistic near-term pathway sees CRISPR-edited allogeneic CAR T products entering later lines of therapy in B-cell cancers in designated centres that already deliver CAR T, with incremental expansion as durability and safety mature. Parallel development efforts in T cell malignancies and early solid tumour targets will iterate on manufacturing and target biology. Trusts will leverage MHRA-enabled point of care frameworks for selected steps where regulatory compliance is required, while most sponsors will continue central manufacture for control and scale. National datasets will link molecular product features with outcomes to refine patient selection and product design.
Limitations and open questions
Key uncertainties remain. For allogeneic products, the durability gap versus autologous therapies is not fully resolved. For solid tumours, trafficking, antigen heterogeneity and immunosuppressive microenvironments still blunt efficacy. Off-target edits appear low in well-controlled products, but long-term consequences require continued surveillance. Finally, affordability will determine real-world reach. Without scalable manufacturing and pragmatic payment models, access will lag science.
Conclusion: a new pillar of cancer care
CRISPR-based medicines have crossed from concept to clinic in haematology and are moving steadily into oncology. The technical promise is clear. Ex vivo edited T cells can be engineered for persistence, potency, and off-the-shelf availability. In vivo editing is advancing as delivery improves. ATMP precedents define the regulatory pathway, updated GMP expectations and managed access mechanisms that share risk between payers and manufacturers. The pharmacy workforce will be essential, from receiving and preparing medications to capturing long-term safety data. If programmes deliver durable benefit with acceptable safety and credible economics, gene editing is positioned to become a third pillar alongside small molecules and biologics in cancer care.
